has announced that it has been granted two product patents, one each from India and South Korea, corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2029 and 2033 respectively. These patents are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Suven has 4 clinical stage compounds, a SUVN-502 (Phase 2), SUVN-G3031 (Phase 2 ready), SUVN-D4010 (Phase 1 completed) and SUVN-911 (Phase 1).
Suven on January 31, 2018, also secured to patents in from African Regional Intellectual Property Organisation (Aripo) and South Korea which are valid through 2033 and 2034 respectively.
Suven Life is currently trading at Rs194, up by Rs2.8 or 1.46% from its previous closing of Rs191.2 on the BSE.